Drug Profile

iTOL 102

Alternative Names: iTOL-102

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator iTolerance
Developer iTolerance; NewcelX
Class Stem cell therapies
Mechanism of Action Pancreatic beta cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Type 1 diabetes mellitus

Most Recent Events

30 Oct 2025 Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX
18 Jul 2025 iTolerance and Kadimastem completes Type-B pre-IND meeting with the US FDA for iTOL 102 for the treatment of type 1 diabetes mellitus
07 Mar 2025 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by iTolerance (iTolerance pipeline, March 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com